209 related articles for article (PubMed ID: 35362187)
1. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
Wang X; Zhao W; Zhang W; Wu S; Yan Z
J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
[TBL] [Abstract][Full Text] [Related]
2. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
3. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
4. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
5. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
[TBL] [Abstract][Full Text] [Related]
6. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
7. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract][Full Text] [Related]
8. IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
Zhao M; He Y; Zhu N; Song Y; Hu Q; Wang Z; Ni Y; Ding L
Br J Cancer; 2023 Mar; 128(5):833-843. PubMed ID: 36463324
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
10. Candida albicans Enhances the Progression of Oral Squamous Cell Carcinoma
Vadovics M; Ho J; Igaz N; Alföldi R; Rakk D; Veres É; Szücs B; Horváth M; Tóth R; Szücs A; Csibi A; Horváth P; Tiszlavicz L; Vágvölgyi C; Nosanchuk JD; Szekeres A; Kiricsi M; Henley-Smith R; Moyes DL; Thavaraj S; Brown R; Puskás LG; Naglik JR; Gácser A
mBio; 2021 Feb; 13(1):e0314421. PubMed ID: 35089096
[TBL] [Abstract][Full Text] [Related]
11. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
12. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
13. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
14. Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma.
Chiu HW; Lin CH; Lee HH; Lu HW; Lin YK; Lin YF; Lee HL
Clin Immunol; 2024 Feb; 259():109892. PubMed ID: 38185269
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Lenouvel D; González-Moles MÁ; Ruiz-Ávila I; Gonzalez-Ruiz L; Gonzalez-Ruiz I; Ramos-García P
Oral Oncol; 2020 Jul; 106():104722. PubMed ID: 32330687
[TBL] [Abstract][Full Text] [Related]
16. Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity.
Saeed S; Rauf F; Iqbal F; Khan AS; Khan AH; Alamgeer R
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4039-4045. PubMed ID: 36579984
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
19. Candida albicans induces TLR2/MyD88/NF-κB signaling and inflammation in oral lichen planus-derived keratinocytes.
Liu J; Geng F; Sun H; Wang X; Zhang H; Yang Q; Zhang J
J Infect Dev Ctries; 2018 Sep; 12(9):780-786. PubMed ID: 31999637
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
